Since 2008 20/20 has been awarded over $2.6 million in grants from the NIST and the NIH to advance development of our L-IHC technology. This funding need not be repaid and is entirely non-dilutive to shareholders.
20/20 was one of only 56 companies nationwide selected to receive a 2007 award for innovative industrial research and development projects from the Advanced Technology Program (ATP), a program of the National Institute of Standards and Technology (NIST).
Technologies selected for ATP funding undergo an extensive, highly competitive, peer-reviewed process that evaluates the scientific and technical merit of each proposal, commercial potential and the potential for broad-based benefits to the nation if the technology were successfully developed.
In July of 2008 20/20 was awarded a $650,000 Phase II SBIR award from the NIH to utilize the L-IHC technology with biomarkers associated with the response of breast tumors to targeted therapies. (This award will be the basis of our 2010 Bridge Award application.)